Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Gross Profit (2018 - 2025)

10x Genomics' Gross Profit history spans 8 years, with the latest figure at $113.0 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 1.88% year-over-year to $113.0 million; the TTM value through Dec 2025 reached $443.9 million, up 7.09%, while the annual FY2025 figure was $443.9 million, 7.09% up from the prior year.
  • Gross Profit for Q4 2025 was $113.0 million at 10x Genomics, up from $100.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $125.1 million in Q2 2025 and bottomed at $86.9 million in Q2 2022.
  • The 5-year median for Gross Profit is $102.5 million (2021), against an average of $104.0 million.
  • The largest annual shift saw Gross Profit skyrocketed 237.65% in 2021 before it decreased 21.66% in 2022.
  • A 5-year view of Gross Profit shows it stood at $115.9 million in 2021, then grew by 3.0% to $119.4 million in 2022, then fell by 3.03% to $115.8 million in 2023, then decreased by 4.17% to $111.0 million in 2024, then rose by 1.88% to $113.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Gross Profit are $113.0 million (Q4 2025), $100.3 million (Q3 2025), and $125.1 million (Q2 2025).